RFK Jr. Overrules FDA, Allows Peptide Drug Sales
Original source
Peptide peddlers cheer as RFK Jr. unilaterally grants access, overruling FDA
Ars Technica →Health Secretary Robert F. Kennedy issued an enforcement discretion policy allowing specialty compounding pharmacies to manufacture and sell six peptides that the FDA had removed from approved compounding lists in 2023. Rather than formally reversing that decision, Kennedy’s policy—titled “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances”—directs HHS to cease enforcement action against pharmacies producing BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500, effectively green-lighting their production starting October 30.
FDA scientists maintain these peptides lack sufficient evidence of effectiveness and carry potential safety risks. Kennedy personally uses some of the peptides and stated he is a “big fan.” The drugs are popular within his Make America Health Again movement, and many prominent figures and Kennedy allies sell them. His enforcement discretion approach sidesteps the formal regulatory process while the FDA’s scientific concerns remain unaddressed.
Read the full article
Continue reading at Ars Technica →This is an AI-generated summary. Read the original for the full story.